CEOs in pharma, biotech, and medtech are increasingly building patient-centric businesses but are struggling to do so. Avoiding five common roadblocks can help leaders build successful businesses. Source: McKinsey The hidden traps of business building: A guide for life science CEOs
Industry economics are shifting toward non-acute care delivery, healthcare software, data, analytics, and specialty pharmacy segments. Source: McKinsey What to expect in US healthcare in 2025 and beyond
Three lighthouse use cases serve as a blueprint for AI’s potential to improve the speed, efficiency, and quality of clinical trials. Source: McKinsey Unlocking peak operational performance in clinical development with artificial intelligence
Leading companies are revamping research and early development to curb lengthy drug development timelines and rising costs. Source: McKinsey Operational excellence in biopharma research and early development
A modern, well-designed tech stack can unlock the potential of AI, automation, and data and their promised benefits to R&D productivity. Source: McKinsey Boosting biopharma R&D performance with a next-generation technology stack
Rapid advancements in science and technology are challenging pharma and biotech companies’ approaches to talent. What R&D skills do they need today, and how can they sustain this workforce? Source: McKinsey Putting people at the center of the R&D talent model in life sciences
Top-performing pharma companies over the past decade have relied on a short list of critical dealmaking behaviors that drive high external innovation productivity. Source: McKinsey External innovation: Biopharma dealmaking to boost R&D productivity
Pharma R&D leaders and their suppliers see transparency as a key to unlocking more effective collaborations and cost efficiencies. Source: McKinsey Building a shared vision for pharma R&D–supplier partnerships
Wharton experts speak with Bill Connelly, staff writer at ESPN.…Read More Source: Knowledge @ Wharton College Football Playoffs with Bill Connelly
Howard Jacob, vice president of genomics research and head of data integration at AbbVie, shares his view on the potential of personalized data, AI, and machine learning to prevent and cure disease. Source: McKinsey AbbVie’s head of genomics research on the transformative power of AI